SG Americas Securities
IOVA icon

SG Americas Securities’s Iovance Biotherapeutics IOVA Stock Holding History

SG Americas Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$880K Buy
211,580
+43,702
+26% +$166K ﹤0.01% 1969
2026
Q1 		$589K Buy
167,878
+112,489
+203% +$360K ﹤0.01% 2089
2025
Q4 		$151K Buy
55,389
+20,626
+59% +$47.7K ﹤0.01% 3040
2025
Q3 		$75K Buy
+34,763
New +$82.1K ﹤0.01% 3137
2025
Q2 		– Sell
-134,765
Closed -$449K – 3256
2025
Q1 		$449K Buy
134,765
+65,140
+94% +$336K ﹤0.01% 1870
2024
Q4 		$515K Buy
+69,625
New +$645K ﹤0.01% 1318
2024
Q3 		– Sell
-498,390
Closed -$4M – 3510
2024
Q2 		$4M Buy
498,390
+445,172
+837% +$4.77M 0.02% 657
2024
Q1 		$789K Sell
53,218
-35,511
-40% -$413K ﹤0.01% 1235
2023
Q4 		$721K Sell
88,729
-187,664
-68% -$982K 0.01% 1233
2023
Q3 		$1.26M Sell
276,393
-91,074
-25% -$595K 0.01% 1085
2023
Q2 		$2.59M Buy
+367,467
New +$2.63M 0.02% 622
2022
Q3 		– Sell
-81,549
Closed -$900K – 3362
2022
Q2 		$900K Sell
81,549
-149,528
-65% -$1.96M 0.01% 1393
2022
Q1 		$3.85M Buy
231,077
+225,452
+4,008% +$3.49M 0.03% 546
2021
Q4 		$107K Sell
5,625
-13,103
-70% -$288K ﹤0.01% 3054
2021
Q3 		$462K Sell
18,728
-3,943
-17% -$92.9K ﹤0.01% 2582
2021
Q2 		$590K Sell
22,671
-318
-1% -$8.27K ﹤0.01% 1868
2021
Q1 		$728K Buy
22,989
+15,458
+205% +$641K ﹤0.01% 1752
2020
Q4 		$349K Sell
7,531
-28,602
-79% -$1.14M ﹤0.01% 2259
2020
Q3 		$1.19M Buy
36,133
+29,560
+450% +$906K 0.01% 1077
2020
Q2 		$180K Sell
6,573
-20,633
-76% -$678K ﹤0.01% 2945
2020
Q1 		$814K Buy
27,206
+5,690
+26% +$151K 0.01% 1443
2019
Q4 		$596K Buy
21,516
+1,825
+9% +$41.5K 0.01% 1627
2019
Q3 		$358K Sell
19,691
-115,410
-85% -$2.55M ﹤0.01% 2065
2019
Q2 		$3.31M Buy
135,101
+65,832
+95% +$992K 0.02% 732
2019
Q1 		$659K Buy
69,269
+48,968
+241% +$476K 0.01% 1595
2018
Q4 		$180K Buy
+20,301
New +$196K ﹤0.01% 2438
2018
Q3 		– Sell
-9,116
Closed -$117K – 3302
2018
Q2 		$117K Sell
9,116
-3,660
-29% -$53.5K ﹤0.01% 2975
2018
Q1 		$216K Buy
+12,776
New +$193K ﹤0.01% 2384
2017
Q4 		– Sell
-50,295
Closed -$390K – 3412
2017
Q3 		$390K Buy
50,295
+39,931
+385% +$253K ﹤0.01% 2033
2017
Q2 		$76K Sell
10,364
-495
-5% -$3.15K ﹤0.01% 2973
2017
Q1 		$81K Sell
10,859
-12,662
-54% -$92.8K ﹤0.01% 3040
2016
Q4 		$163K Buy
+23,521
New +$162K ﹤0.01% 2512
2015
Q4 		– Sell
-10,578
Closed -$61K – 2840
2015
Q3 		$61K Buy
+10,578
New +$82.4K ﹤0.01% 1946

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

SG Americas Securities's IOVA Position: Q2 2026 in Review

SG Americas Securities increased its Iovance Biotherapeutics (IOVA) stake by 26% in Q2 2026, buying an estimated $166K and bringing the position to 211,580 shares worth $880K. The position accounts for ﹤0.01% of the portfolio, ranked #1969.

SG Americas Securities first reported a position in IOVA in Q3 2015 and has held it in 33 quarters since. The position peaked at $4M in Q2 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • SG Americas Securities held 211,580 shares of Iovance Biotherapeutics worth $880K as of Q2 2026.
  • SG Americas Securities bought 43,702 Iovance Biotherapeutics shares in Q2 2026, an estimated $166K.
  • Iovance Biotherapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1969 holding.
  • SG Americas Securities first reported a position in Iovance Biotherapeutics in Q3 2015 and has held it in 33 quarters since.
  • SG Americas Securities's Iovance Biotherapeutics position peaked at $4M in Q2 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.